"Let Me Down Easy" By Anna Deveare Smith

Event Chairmen Paul Pescatello, President, CURE David Scheer, President, Scheer & Co SIGN UP EARLY Supper and Arts Outing at Long Wharf for Connecticut's pharma and biotech communities Wednesday, January 30, 2008 Supper: 5 - 6:45 pm Theater Curtain: 7 pm "Let Me Down Easy" by Tony-award winning playwright and actress Anna Deveare Smith Winner of a MacArthur Foundation "genius" fellowship and hailed by Newsweek as "the most exciting individual in American theatre" This one-woman show about the resilience and fragility of the human body debuted at Yale Medical School where Smith was a visiting professor. at New Haven's nationally known Long Wharf Theatre This is an exciting opportunity to see a play before it heads for New York City. Bring your spouse. Share this with colleagues and friends. Before the show, join us for supper at Leon's (formerly the Rusty Scupper) Hear about the play from the producers. Learn about another New Haven arts jewel, The New Haven Symphony. Seats are limited. They will be distributed first come, first served. SIGN UP EARLY Click here for directions to the theater Click here for directions to the restaurant Cost for employees of CURE members and their guests (per person): $45 Theater only. $68 Theater and Dinner Cost for non members (per person): $50 Theater only. $110 per person. Click here to find out if your company is a CURE member All profits go to DEVELOPING WORLD CURES. This new New Haven non-profit is dedicated to developing medicines, assays and devices to treat diseases prevelant in the developing world for which existing treatments are not effective or suitable.

CURE & YALE University: Yale BioHaven Enterprenurship

Tuesday, February 12, 2008 Rib-X Pharmaceuticals, Inc. Followed by networking, refreshments & wine bar Rib-X Pharmaceuticals, Inc. is focused on the design and development of novel small-molecule antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. Since its inception in 2001, Rib-X has established a portfolio of development and discovery-stage compounds that address various segments in the diverse antibiotic marketplace, including RX-3341, a broad spectrum quinolone antibiotic which will soon enter Phase 3 studies as an IV agent and RX-1741, an oxazolidinone antibiotic now in two Phase 2 studies as an oral agent. Many classical antibiotics work by inhibiting the function of the ribosome. A key competitive advantage for Rib-X is its proprietary access to the high-resolution crystal structure of the ribosome, a molecule which is essential for the viability of all bacterial pathogens and the target of numerous valuable antibiotics. Rib-X's research goal is to use chemical and physical information from the three-dimensional structure of the ribosome to design proprietary classes of antibacterial agents that have activity against newly emerging multiple antibiotic-resistant microorganisms. Structural and computational data about how ligands block the function of this complex molecular machine are being used to prime parallel lead optimization programs focused on new chemistry ideas about the multiple binding domains or drug targets within the ribosome. The scope of the Rib-X structure based design process will enable the Company to fully exploit the chemistry of the ribosome and build a pipeline of diverse products and as a result a sustainable franchise. Rib-X raised $50 million in a Series C Preferred Stock financing announced in June of 2006. The round was led by existing investor Warburg Pincus, the global private equity investment firm. That round of financing brought the total amount raised by the company to $123 million. Speakers Susan Froshauer, Ph.D. President & Chief Executive Officer, Rib-X Pharmaceuticals, Inc. Erin Duffy, Ph.D. Vice President, Structure Based Drug Design, Rib-X Pharmaceuticals, Inc. Tuesday, February 12, 2008 3:30 P.M. Registration 4:00 P.M. Seminar 5:00 P.M. Networking, Refreshments & Wine Bar Location The Anlyan Center auditorium, Yale Medical School. Directions & Parking: http://info.med.yale.edu/maps/cab.html RSVP Registration is free, but please RSVP in advance. E-mail to biohaven@yale.edu or call the Yale OCR main number: 203-785-6209. Mark Your Calendar The next seminar in the series, on March 19, 2008, features Optherion, Inc. Download a brochure of the complete 2007-2008 series here. Lead sponsors: Wiggin and Dana and PricewaterhouseCoopers. Also sponsored by Elm Street Ventures. Presented by CURE and the Yale Office of Cooperative Research. Additional support from the Yale Entrepreneurial Society and the Yale Biotechnology & Pharmaceutical Society. Published by Connecticut United for Research Excellence Copyright © 2008 Connecticut United for Research Excellence. All rights reserved. Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org TELL A FRIEND

Powered by IMN™ this e-mail was sent to drmuni From Connecticut United for Research Excellence, 300 George Street, New Haven, CT 06511 USA

2008 CIO of the Year Awards By Pittsburgh Technology Counsil

2008 CIO of the Year Awards
The CIO of the Year Awards honor technology executives that breathe life into the region with their creativity and innovative ideas. Join the Greater Pittsburgh CIO Group, UPMC and the Pittsburgh Technology Council to honor industry, academic, government and non-profit visionaries that reach for the limits.

At the awards, Dr. Kevin Elko, former Penguins Performance Coach and nationally renowned sports psychologist and speaker, will motivate you to succeed with his proven inspiration methods.

Also, last year's winners Jinx Walton from the University of Pittsburgh, Mark Miko from The Armstrong Group of Companies, and Andy Roach from Ketchum will participate in a short panel discussion.

Technology managers and executives; IT professionals of all types; media representatives; sales, marketing and business development staff from IT firms; as well as government and academic leaders will not want to miss this event.

Get your head out of the clouds and register today!

Date: Wednesday, February 6
Time: 5:30 - 8:30 p.m.
Venue: Westin Convention Center
Member Cost: $50, $350 for table of eight
Non-Member Cost: $75, $350 for table of eight
Register: www.pghcio.com, Council Events or 412.918.4229

BioSpace Career Fari in New Jersey!!

BioSpace:
A web based resource and information provider to the Life Science industries such as Biotech, Pharma and other bio companies.
The following career fair is arranged by BioSpace that might be very useful to job seekers as well to professionals, companies and all. Check this out in New Jersey next month

The BioSpace Career Fair is Coming to
Bridgewater, New Jersey!

BioSpace is proud to present the Pharm Country Career Fair on Monday, February 4, 2008, from 2pm to 7pm at the Bridgewater Marriott in Bridgewater, New Jersey.

Do not miss the chance to interview with the biopharmaceutical industry's most prestigious companies! Hundreds of positions are available with industry leaders such as: Allergan Amicus Therapeutics, Inc. Covance, Inc. Enzon Pharmaceuticals Forest Laboratories Inc. Galderma Research & Development ImClone Systems OSI Pharmaceuticals Otsuka America Pharmaceuticals Regeneron Pharmaceuticals, Inc. Vertex Pharmaceuticals and more All candidates must have at least a four-year college degree and two years of industry related work experience to attend. (Equivalent work experience may be considered in lieu of a four-year college degree.) Qualified candidates will receive their invitations and confirmation numbers via email 24 to 48 hours after their resumes have been submitted. Pre-screened and accepted candidates must bring a copy of their invitation with confirmation number to the event. We look forward to seeing you at the BioSpace Career Fair! BioSpace Career Fair Team 888-750-4473

Biotech Bay Career Fair February 4, 2008 Burlingame, California Pharm Country Career Fair February 4, 2008 Bridgewater, New Jersey Genetown Career Fair February 19, 2008 Cambridge, Massachusetts DeviceSpace Career Fair March 17, 2008 Irvine, California Pharm Country Career Fair April 1, 2008 King of Prussia, Pennsylvania BioMidwest Career Fair April 15, 2008 Oak Brook, Illinois BioCapital Career Fair April 17, 2008 Bethesda, Maryland

HOUSING BURST?: Eastern States are the Hardest hit in housing market?

Northeast Is Toughest Place in U.S. to Sell Homes (Update2)
By Kathleen M. Howley
Jan. 8 (Bloomberg) -- The toughest place to sell a home in the U.S. in November was the Northeast as homebuyers sat on the sidelines in an area that has seen the biggest price gains.
An index measuring signed contracts for previously owned homes fell 13 percent in the region, the most in the country, the National Association of Realtors said today in a report. Prices there jumped more than sixfold over the past 26 years, leading the U.S., according to the Office of Federal Housing Enterprise Oversight, or Ofheo.
*********************************************
The pending sale index's drop in states including New York, New Jersey, Massachusetts and Connecticut was triple other U.S. regions and demonstrates home sellers are having to lower expectations as the real estate slump worsens. Nationally, the number of Americans signing contracts to buy previously owned homes fell 2.6 percent in November from October, according to the Realtors' Pending Home Sales Index.
``The northeast is getting hit hard,'' said Paul Rinkulis, an agent at Keliher Real Estate in Boston. ``It's at least as bad as it was in the late 1980s, early 1990s, and that was bad.''
The Realtors report showed pending resales fell in three of four regions. In addition to the Northeast's 13 percent drop, the pending sales index decreased 4.1 percent in the Midwest and 2.1 percent in the West. The pending sales rose 2.3 percent in the South. The figures are seasonally adjusted.
******************************